AFR, which takes both Alb and Fib into account, has been indicated as a prognostic factor for various malignancies, including non-small cell lung cancer (43), chronic lymphocytic leukemia (44), and breast cancer (45). Here, ALB is linked to non-small cell lung carcinoma.